## Herbert Pang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6174411/publications.pdf

Version: 2024-02-01

|          |                | 279701       | 182361         |
|----------|----------------|--------------|----------------|
| 68       | 2,761          | 23           | 51             |
| papers   | citations      | h-index      | g-index        |
|          |                |              |                |
|          |                |              |                |
| 70       | 70             | 70           | 4513           |
| all docs | docs citations | times ranked | citing authors |
|          |                |              |                |

| #  | Article   | IF       | CITATIONS    |
|----|---|----------|--------------|
| 1  | Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With<br>Chemotherapy-Induced Painful Peripheral Neuropathy. JAMA - Journal of the American Medical<br>Association, 2013, 309, 1359.  | 3.8      | 785          |
| 2  | Pathway analysis using random forests classification and regression. Bioinformatics, 2006, 22, 2028-2036.   | 1.8      | 210          |
| 3  | VATS Lobectomy Has Better Perioperative Outcomes Than Open Lobectomy: CALGB 31001, an Ancillary Analysis of CALGB 140202 (Alliance). Annals of Thoracic Surgery, 2015, 99, 399-405.   | 0.7      | 170          |
| 4  | A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307. Journal of Thoracic Oncology, 2010, 5, 1655-1661.  | 0.5      | 115          |
| 5  | Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance). Clinical Cancer Research, 2013, 19, 6957-6966.  | 3.2      | 95           |
| 6  | Normative data and psychometric properties of the Connor–Davidson Resilience Scale (CD-RISC) and the abbreviated version (CD-RISC2) among the general population in Hong Kong. Quality of Life Research, 2016, 25, 111-116.   | 1.5      | 76           |
| 7  | Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Medicine, 2013, 2, 234-242.   | 1.3      | 64           |
| 8  | Composition of gut microbiota in infants in China and global comparison. Scientific Reports, 2016, 6, 36666.  | 1.6      | 63           |
| 9  | Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and) Tj ETQq1 1  | 0.784314 | rggT /Overlo |
| 10 | A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer. Oncologist, 2011, 16, 1131-1137.   | 1.9      | 58           |
| 11 | Cohort Profile: FAMILY Cohort. International Journal of Epidemiology, 2017, 46, e1-e1.  | 0.9      | 58           |
| 12 | Gene Selection Using Iterative Feature Elimination Random Forests for Survival Outcomes. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2012, 9, 1422-1431.   | 1.9      | 54           |
| 13 | Effect of machine learning re-sampling techniques for imbalanced datasets in 18F-FDG PET-based radiomics model on prognostication performance in cohorts of head and neck cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2826-2835. | 3.3      | 54           |
| 14 | Preventing Respiratory Tract Infections by Synbiotic Interventions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Advances in Nutrition, 2020, 11, 979-988.  | 2.9      | 51           |
| 15 | A Pooled Analysis of Limited-Stage Small-Cell Lung Cancer Patients Treated with Induction<br>Chemotherapy Followed by Concurrent Platinum-Based Chemotherapy and 70 Gy Daily Radiotherapy:<br>CALGB 30904. Journal of Thoracic Oncology, 2013, 8, 1043-1049.                | 0.5      | 49           |
| 16 | Shrinkageâ€based Diagonal Discriminant Analysis and Its Applications in Highâ€Dimensional Data.<br>Biometrics, 2009, 65, 1021-1029.   | 0.8      | 48           |
| 17 | Longitudinal Patterns and Predictors of Depression Trajectories Related to the 2014 Occupy<br>Central/Umbrella Movement in Hong Kong. American Journal of Public Health, 2017, 107, 593-600.  | 1.5      | 46           |
| 18 | A leave-one-out cross-validation SAS macro for the identification of markers associated with survival. Computers in Biology and Medicine, 2015, 57, 123-129.  | 3.9      | 45           |

| #  | Article  | IF  | Citations |
|----|--|-----|-----------|
| 19 | Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations. PLoS Genetics, 2018, 14, e1007779.   | 1.5 | 44        |
| 20 | Pathway analysis using random forests with bivariate node-split for survival outcomes. Bioinformatics, 2010, 26, 250-258.  | 1.8 | 38        |
| 21 | Radiomics Model to Predict Early Progression of Nonmetastatic Nasopharyngeal Carcinoma after Intensity Modulation Radiation Therapy: A Multicenter Study. Radiology: Artificial Intelligence, 2019, 1, e180075.                      | 3.0 | 32        |
| 22 | Sample Size Considerations of Predictionâ€Validation Methods in Highâ€Dimensional Data for Survival Outcomes. Genetic Epidemiology, 2013, 37, 276-282.   | 0.6 | 29        |
| 23 | Building pathway clusters from Random Forests classification using class votes. BMC Bioinformatics, 2008, 9, 87.   | 1.2 | 28        |
| 24 | Modulation of circulating protein biomarkers following TRC 105 (antiâ€endoglin antibody) treatment in patients with advanced cancer. Cancer Medicine, 2014, 3, 580-591.  | 1.3 | 27        |
| 25 | A comparison of graph- and kernel-based $\hat{a}\in$ omics data integration algorithms for classifying complex traits. BMC Bioinformatics, 2017, 18, 539.  | 1.2 | 26        |
| 26 | Direct Participation in and Indirect Exposure to the Occupy Central Movement and Depressive Symptoms: A Longitudinal Study of Hong Kong Adults. American Journal of Epidemiology, 2016, 184, 636-643.                                | 1.6 | 25        |
| 27 | Phase II Study of Induction Cisplatin and Irinotecan Followed by Concurrent Carboplatin, Etoposide, and Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer, CALGB 30206. Journal of Thoracic Oncology, 2013, 8, 102-108. | 0.5 | 23        |
| 28 | Determinants of physical, mental and social well-being: a longitudinal environment-wide association study. International Journal of Epidemiology, 2020, 49, 380-389.   | 0.9 | 23        |
| 29 | Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer<br>Patients Receiving Bevacizumab and Everolimus. Molecular Cancer Therapeutics, 2015, 14, 1048-1056.                                | 1.9 | 22        |
| 30 | Shrinkage-based diagonal Hotelling's tests for high-dimensional small sample size data. Journal of Multivariate Analysis, 2016, 143, 127-142.  | 0.5 | 22        |
| 31 | Pathway-based identification of SNPs predictive of survival. European Journal of Human Genetics, 2011, 19, 704-709.  | 1.4 | 19        |
| 32 | Bloodâ€based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from <scp>CALGB</scp> 80203 (Alliance). Cancer Medicine, 2016, 5, 2249-2260.   | 1.3 | 19        |
| 33 | A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist, 2018, 23, 782-790.  | 1.9 | 19        |
| 34 | Bacteriophage of the Skin Microbiome in Patients with Psoriasis and Healthy Family Controls. Journal of Investigative Dermatology, 2020, 140, 182-190.e5.  | 0.3 | 19        |
| 35 | Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status. Lung Cancer, 2017, 114, 79-89.  | 0.9 | 17        |
| 36 | Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105. Molecular Cancer Therapeutics, 2018, 17, 2248-2256.  | 1.9 | 17        |

3

| #  | Article   | IF  | Citations |
|----|---|-----|-----------|
| 37 | Bayesian semiparametric regression models for evaluating pathway effects on continuous and binary clinical outcomes. Statistics in Medicine, 2012, 31, 1633-1651.   | 0.8 | 16        |
| 38 | Reporting and guidelines for mendelian randomization analysis: A systematic review of oncological studies. Cancer Epidemiology, 2019, 62, 101577.   | 0.8 | 16        |
| 39 | Role of dietary carbohydrates on risk of lung cancer. Lung Cancer, 2021, 155, 87-93.  | 0.9 | 16        |
| 40 | Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women. Genomics, 2020, 112, 1223-1232.  | 1.3 | 15        |
| 41 | A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limitedâ€stage small cell lung cancer in elderly patients versus younger patients. Cancer, 2019, 125, 382-390. | 2.0 | 14        |
| 42 | Pathway-Based Single-Cell RNA-Seq Classification, Clustering, and Construction of Gene-Gene Interactions Networks Using Random Forests. IEEE Journal of Biomedical and Health Informatics, 2020, 24, 1814-1822.                                       | 3.9 | 13        |
| 43 | Transmissibility of the Ice Bucket Challenge among globally influential celebrities: retrospective cohort study. BMJ, The, 2014, 349, g7185-g7185.  | 3.0 | 11        |
| 44 | Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist, 2017, 22, 189-198.    | 1.9 | 9         |
| 45 | Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer. Lung Cancer, 2020, 141, 14-20.   | 0.9 | 9         |
| 46 | Random Effects Model for Multiple Pathway Analysis with Applications to Type II Diabetes Microarray Data. Statistics in Biosciences, 2015, 7, 167-186.  | 0.6 | 8         |
| 47 | Endpoint surrogacy in oncology Phase 3 randomised controlled trials. British Journal of Cancer, 2020, 123, 333-334.   | 2.9 | 8         |
| 48 | A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2015, 75, 343-352.   | 1.1 | 7         |
| 49 | Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data. Cancer Informatics, 2014, 13s4, CIN.S13634.   | 0.9 | 6         |
| 50 | Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. Lung Cancer, 2015, 90, 281-287.  | 0.9 | 6         |
| 51 | Seamless Phase IIa/IIb and enhanced dose-finding adaptive design. Journal of Biopharmaceutical Statistics, 2016, 26, 912-923.   | 0.4 | 6         |
| 52 | Clinical prognostic model for older patients with advanced non-small cell lung cancer. Journal of Geriatric Oncology, 2019, 10, 555-559.  | 0.5 | 6         |
| 53 | Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. Clinical Cancer Research, 2015, 21, 3442-3452.  | 3.2 | 5         |
| 54 | Change in moderate alcohol consumption and quality of life: evidence from 2 population-based cohorts. Cmaj, 2019, 191, E753-E760.   | 0.9 | 5         |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Analysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis. Human Genomics, 2010, 5, 5.   | 1.4 | 4         |
| 56 | Block-diagonal discriminant analysis and its bias-corrected rules. Statistical Applications in Genetics and Molecular Biology, 2013, 12, 347-59.                                      | 0.2 | 4         |
| 57 | Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.<br>Investigational New Drugs, 2014, 32, 700-709.                                    | 1.2 | 4         |
| 58 | Bias-adjusted Kaplan–Meier survival curves for marginal treatment effect in observational studies.<br>Journal of Biopharmaceutical Statistics, 2019, 29, 592-605.                     | 0.4 | 4         |
| 59 | Diffusion-weighted magnetic resonance imaging of primary cervical cancer in the detection of sub-centimetre metastatic lymph nodes. Cancer Imaging, 2020, 20, 27.                     | 1.2 | 4         |
| 60 | Stratified Pathway Analysis to Identify Gene Sets Associated with Oral Contraceptive Use and Breast Cancer. Cancer Informatics, 2014, 13s4, CIN.S13973.                               | 0.9 | 3         |
| 61 | Methodological Considerations in the Design and Implementation of Clinical Trials. Seminars in Oncology Nursing, 2014, 30, 74-79.   | 0.7 | 3         |
| 62 | Bayesian Semiparametric Model for Pathway-Based Analysis with Zero-Inflated Clinical Outcomes. Journal of Agricultural, Biological, and Environmental Statistics, 2016, 21, 641-662.  | 0.7 | 3         |
| 63 | Development and Validation of a Natural Language Processing Tool to Generate the CONSORT<br>Reporting Checklist for Randomized Clinical Trials. JAMA Network Open, 2020, 3, e2014661. | 2.8 | 3         |
| 64 | Statistical aspect of translational and correlative studies in clinical trials. Chinese Clinical Oncology, 2016, 5, 11.   | 0.4 | 1         |
| 65 | Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies. Chinese Clinical Oncology, 2022, 11, 7-7.     | 0.4 | 1         |
| 66 | Pathwayâ€based metaâ€analysis for partially paired transcriptomics analysis. Research Synthesis Methods, 2020, 11, 123-133.   | 4.2 | 0         |
| 67 | An enhanced machine learning tool for cis â€eQTL mapping with regularization and confounder adjustments. Genetic Epidemiology, 2020, 44, 798-810.                                     | 0.6 | 0         |
| 68 | Assessing surrogacy using restricted mean survival time ratio for overall survival in liver cancer immunotherapy studies Journal of Clinical Oncology, 2022, 40, e16222-e16222.       | 0.8 | 0         |